These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 7521509)
1. Effective induction of human NK cells with OK-432 and further augmentation of their cytolytic function by rIL-2. Hu ZL; Kubota E; Imamura H; Katano M; Katsuki T Microbiol Immunol; 1994; 38(3):183-90. PubMed ID: 7521509 [TBL] [Abstract][Full Text] [Related]
2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2. Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906 [TBL] [Abstract][Full Text] [Related]
3. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954 [TBL] [Abstract][Full Text] [Related]
4. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599 [TBL] [Abstract][Full Text] [Related]
5. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432. Wakasugi H; Kasahara T; Minato N; Hamuro J; Miyata M; Morioka Y J Natl Cancer Inst; 1982 Oct; 69(4):807-12. PubMed ID: 6181282 [TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells. Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412 [TBL] [Abstract][Full Text] [Related]
7. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057 [TBL] [Abstract][Full Text] [Related]
8. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone. Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882 [TBL] [Abstract][Full Text] [Related]
9. OK-432 and IL-2-augmented cytotoxicity of human natural killer cells and cytotoxic T lymphocytes at the clonal level. Gravekamp C; Vreugdenhil R; Bolhuis RL FEMS Microbiol Immunol; 1988 Jan; 1(1):31-9. PubMed ID: 2978812 [TBL] [Abstract][Full Text] [Related]
10. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity. Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440 [TBL] [Abstract][Full Text] [Related]
11. Costimulatory signals are required for optimal proliferation of human natural killer cells. Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691 [TBL] [Abstract][Full Text] [Related]
12. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283 [TBL] [Abstract][Full Text] [Related]
14. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959 [TBL] [Abstract][Full Text] [Related]
15. Role of CD16 (Fc receptor III) and interleukin-2 in the reactivation of natural killer cells after inhibitory target cell contact. Heiskala M; Ståhls A; Seppälä I; Timonen T Nat Immun Cell Growth Regul; 1991; 10(5):265-77. PubMed ID: 1836835 [TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. Lanier LL; Benike CJ; Phillips JH; Engleman EG J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of tyrosine kinase inhibition in CD69 antigen expression and lytic activity induced by rIL-2, rIL-12, and rIFN-alpha in human NK cells. Gerosa F; Tommasi M; Benati C; Gandini G; Libonati M; Tridente G; Carra G; Trinchieri G Cell Immunol; 1993 Sep; 150(2):382-90. PubMed ID: 8103709 [TBL] [Abstract][Full Text] [Related]
18. Cell populations in the human early pregnancy decidua: natural killer activity and response to interleukin-2 of CD56-positive large granular lymphocytes. Ferry BL; Starkey PM; Sargent IL; Watt GM; Jackson M; Redman CW Immunology; 1990 Aug; 70(4):446-52. PubMed ID: 1697563 [TBL] [Abstract][Full Text] [Related]
19. Purified human T cells stimulated with cross-linked anti-CD3 monoclonal antibody OKT3: rIL-1 is a co-stimulatory factor for CD4+CD29+CD45RA- T cells. Panzer S; Geller RL; Bach FH Scand J Immunol; 1990 Oct; 32(4):359-71. PubMed ID: 1700468 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of recombinant human interleukin-2: biological features and clinical relevance. Hänninen EL; Knüver-Hopf J; Atzpodien J Biotherapy; 1993; 6(4):251-61. PubMed ID: 7517168 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]